RS BioTherapeutics Appoints Pharmaceutical Industry Veteran Dean Hart as Chief Executive Officer
10 avr. 2023 11h00 HE
|
RS BioTherapeutics
CUMBERLAND, Md., April 10, 2023 (GLOBE NEWSWIRE) -- RS BioTherapeutics, whose mission is to harness the therapeutic power of cannabinoids in the research, development, and commercialization of life...
RS BioTherapeutics Selects Recipharm as Product Characterization Partner
14 nov. 2022 10h00 HE
|
RS BioTherapeutics
CUMBERLAND, Md., Nov. 14, 2022 (GLOBE NEWSWIRE) -- RS BioTherapeutics, whose mission is to harness its strong and thorough understanding of the endocannabinoid system (ECS) to research, develop and...
RS BioTherapeutics Secures $3 Million Seed II Round of Funding
26 sept. 2022 09h34 HE
|
RS BioTherapeutics
CUMBERLAND, Md., Sept. 26, 2022 (GLOBE NEWSWIRE) -- RS BioTherapeutics, whose mission is to harness its strong and thorough understanding of the endocannabinoid system (ECS) to research, develop and...
RS Biotherapeutics Appoints Jeremy Plumb as Chief Cultivation Officer
01 août 2022 10h00 HE
|
RS BioTherapeutics
CUMBERLAND, Md., Aug. 01, 2022 (GLOBE NEWSWIRE) -- RS BioTherapeutics, whose mission is to harness its strong and thorough understanding of the endocannabinoid system (ECS) to research, develop and...
RS Biotherapeutics Reports Positive Results From Proof-of-Concept Trial for First Investigational Compound
11 juil. 2022 11h00 HE
|
RS BioTherapeutics
CUMBERLAND, Md., July 11, 2022 (GLOBE NEWSWIRE) -- RS BioTherapeutics, whose mission is to harness its strong and thorough understanding of the endocannabinoid system (ECS) to research, develop and...
RS BioTherapeutics Enters Into License Agreement With Synthonics for First Investigational Compound
23 mai 2022 11h00 HE
|
RS BioTherapeutics
CUMBERLAND, Md., May 23, 2022 (GLOBE NEWSWIRE) -- RS BioTherapeutics, whose mission is to harness its strong and thorough understanding of the endocannabinoid system to research, develop and...